In vitro evaluation of cellular migration and invasion in breast cancer in response to treatment with metiformin and Y27632 after induction process of epithelial mesenchymal transition.

• Grant number: 12/15592-8
• Support type: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): December 01, 2012
• Effective date (End): November 30, 2013
• Field of knowledge: Agronomical Sciences - Veterinary Medicine
• Principal researcher: Debora Aparecida Pires de Campos Zuccari
• Grantee: Michel Raineri Haddad
• Home Institution: Faculdade de Medicina de São José do Rio Preto (FAMERP). Secretaria de Desenvolvimento Econômico (São Paulo - Estado). São José do Rio Preto , SP, Brazil

Abstract

The breast cancer is the worldwide most commom neoplasia in women, and its malignancy centered on its highly invasive and metastatic actions. The expression of ROCK-1 is associated with malignant, whereas inhibition of this signaling molecule results in a significant suppression of tumor metastasis. Likewise, the transforming growth factor beta (TGF-²) has been linked to its power to induce epithelial-mesenchymal transition (EMT), which provides greater mobility and an invasive phenotype of these tumor cells. However, new therapeutic options have been used to inhibit these processes, in which metformin, a drug used to treat type 2 diabetes, has shown good results in research on breast cancer, reducing its incidence and prognosis favoring, through mechanisms not completely understood, but involving, among many other markers, TGF-². From the effect of TGF-² and protein expression of ROCK-1 in promoting cancer malignancy, we intend to evaluate the effects of metformin with or without the ROCK inhibitor-1, Y27632, and alternative therapies for inhibition of metastasis breast cancer in vitro.